175 related articles for article (PubMed ID: 19503093)
1. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
Pulukuri SM; Gorantla B; Knost JA; Rao JS
Oncogene; 2009 Aug; 28(31):2829-38. PubMed ID: 19503093
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG; Jones WD; Coleman WB
Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
[TBL] [Abstract][Full Text] [Related]
3. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
4. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
[TBL] [Abstract][Full Text] [Related]
5. TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC; Higgins C; Ong CW; Irwin GW; Boyle D; McArt DG; McCloskey K; Buckley NE; Crawford NT; Thiagarajan L; Murray JT; Kennedy RD; Mulligan KA; Harkin DP; Waugh DJ; Scott CJ; Salto-Tellez M; Williams R; Mullan PB
Oncotarget; 2014 Mar; 5(6):1609-20. PubMed ID: 24742492
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
[TBL] [Abstract][Full Text] [Related]
7. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG; Livasy CA; Boyd CE; Keppler D; Coleman WB
Exp Mol Pathol; 2007 Oct; 83(2):188-97. PubMed ID: 17540367
[TBL] [Abstract][Full Text] [Related]
8. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
9. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
Luo W; Karpf AR; Deeb KK; Muindi JR; Morrison CD; Johnson CS; Trump DL
Cancer Res; 2010 Jul; 70(14):5953-62. PubMed ID: 20587525
[TBL] [Abstract][Full Text] [Related]
11. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.
Jin L; Zhang Y; Li H; Yao L; Fu D; Yao X; Xu LX; Hu X; Hu G
Cell Res; 2012 Sep; 22(9):1356-73. PubMed ID: 22688893
[TBL] [Abstract][Full Text] [Related]
12. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Yamada Y; Watanabe M; Yamanaka M; Hirokawa Y; Suzuki H; Takagi A; Matsuzaki T; Sugimura Y; Yatani R; Shiraishi T
Cancer Sci; 2003 Jun; 94(6):536-9. PubMed ID: 12824880
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
16. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
[TBL] [Abstract][Full Text] [Related]
17. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
20. The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea.
Zeeuwen PL; van Vlijmen-Willems IM; Cheng T; Rodijk-Olthuis D; Hitomi K; Hara-Nishimura I; John S; Smyth N; Reinheckel T; Hendriks WJ; Schalkwijk J
FASEB J; 2010 Oct; 24(10):3744-55. PubMed ID: 20495178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
